

Estimate change	↔
TP change	↔
Rating change	↔

Bloomberg	SRF IN
Equity Shares (m)	297
M.Cap.(INRb)/(USDb)	646.6 / 7.8
52-Week Range (INR)	2640 / 2040
1, 6, 12 Rel. Per (%)	0/-20/-20
12M Avg Val (INR M)	1302

Financials & Valuations (INR b)

Y/E Mar	2023	2024E	2025E
Sales	148.7	142.0	174.2
EBITDA	36.3	30.0	41.7
PAT	22.7	15.9	24.0
EBITDA (%)	24.4	21.1	24.0
EPS (INR)	76.2	53.6	80.6
EPS Gr. (%)	24.8	(29.6)	50.2
BV/Sh. (INR)	347	387	453

Ratios

Net D/E	0.3	0.4	0.4
RoE (%)	24.0	14.6	19.2
RoCE (%)	17.9	11.6	14.9
Payout (%)	9.9	23.0	18.6

Valuations

P/E (x)	28.6	40.7	27.1
EV/EBITDA (x)	18.8	23.0	16.7
Div Yield (%)	0.3	0.5	0.7
FCF Yield (%)	(0.0)	(0.5)	0.3

Shareholding pattern (%)

As On	Sep-23	Jun-23	Sep-22
Promoter	50.5	50.5	50.5
DII	14.2	13.7	14.0
FII	19.8	20.0	19.2
Others	15.6	15.7	16.2

Note: FII includes depository receipts

CMP: INR2,181 TP: INR2,000 (-8%) Neutral

Chemicals and Packaging business drags overall profitability

Operating profitability in line with estimate

- SRF reported subdued operating performance for the second consecutive quarter in 2QFY24 (EBIT declined 27% YoY), led by continuing weakness in Chemical/Packaging Film business (EBIT dipped 33%/24% YoY), offsetting recovery in the Technical textile business (EBIT up 19% YoY).
- We maintain our FY24/FY25 EBITDA estimates and value the stock at SoTP-based TP of INR2,000. We reiterate our **NEUTRAL** rating on the stock.

Weak demand and lower realization impact revenue

- SRF reported overall revenue of INR31.7b (est. of INR33.2) in 2QFY24, down 15% YoY. EBITDA margins contracted 130bp YoY to 20.3% (est. of 19.5%). EBITDA stood at INR6.5b (in line with est.), down 20% YoY. Adj. PAT declined 38% YoY to INR3.2b (est. of INR3.4b).
- Chemicals'** revenue (45%/65% of total sales/EBIT in 2QFY24) dropped 22% YoY to INR14.3b; while EBIT declined 33% YoY to INR3.5b. EBIT margin contracted 390bp YoY to 24.4%. The Chemicals business was hit by low demand for refrigerant and inventory rationalization in specialty chemicals. Further, sluggish growth in the pharmaceuticals and agrochemical industries adversely impacted the demand for industrial chemicals.
- Packaging Film's** revenue (35%/15% of total sales/EBIT in 2QFY24) declined 16% YoY to INR11.2b and EBIT was down 24% YoY to INR773m. Margin contracted 70bp YoY to 6.9%. The packaging film business continues to face headwinds due to substantial supply additions in both BOPET and BOPP film segments. This has led to margin pressures and an overall global demand slowdown.
- Technical Textiles'** revenue (16%/14% of total sales/EBIT in 2QFY24) grew 9% YoY to INR5.1b; EBIT margin expanded 130bp YoY to 14.8%. EBIT grew 19% YoY to INR750m. The segment performed well on the back of higher sales volume in Nylon Tyre Cord Fabric.
- For 1HFY24, SRF's revenue/EBITDA/Adj. PAT declined 15%/25%/39% YoY to INR65.2b/INR13.7b/INR7b.

Highlights from the management commentary

- Inventory rationalization within the **Specialty Chemicals** segment is expected to be transitory as orders are getting postponed and not cancelled. Management expects single-digit growth in the specialty chemical segment for FY24.
- Fluorochemicals segment** witnessed subdued performance as the Chinese dumping led to low demand and weak prices for the key refrigerants. The traction in demand is expected to be much stronger in 2HFY24.
- Capex:** Management plans to incur ~INR29-30b/INR28-30b of capex in FY24/FY25, with ~80% of capex to be incurred within the chemicals segment

Sumant Kumar - Research Analyst (Sumant.Kumar@MotilalOswal.com)

Research Analyst: Meet Jain (Meet.Jain@MotilalOswal.com) / **Omkar Shintre** (Omkar.Shintre@MotilalOswal.com)

Investors are advised to refer through important disclosures made at the last page of the Research Report.

Motilal Oswal research is available on www.motilaloswal.com/Institutional-Equities, Bloomberg, Thomson Reuters, Factset and S&P Capital.

Valuation and view

- The Chemicals and Packaging business margins are expected to remain under pressure in FY24, led by weak demand scenario and lower realization. However, we expect the packaging performance to improve from FY25.
- We maintain our FY24/FY25 EBITDA estimates and value the stock at SoTP-based TP of INR2,000. We reiterate our **NEUTRAL** rating on the stock.

Consolidated - Quarterly Earning Model

(INR m)


Y/E March	FY23				FY24E				FY23	FY24E	FY24E	Var %
	1Q	2Q	3Q	4Q	1Q	2Q	3QE	4QE				
Net Sales	38,947	37,278	34,697	37,781	33,384	31,774	36,081	40,728	1,48,703	1,41,967	33,222	-4
YoY Change (%)	44.3	31.3	3.7	6.4	-14.3	-14.8	4.0	7.8	19.6	-4.5	-10.9	
Total Expenditure	28,749	29,226	26,211	28,185	26,184	25,320	28,704	31,733	1,12,371	1,11,941	26,749	
EBITDA	10,198	8,052	8,486	9,596	7,200	6,453	7,378	8,995	36,332	30,026	6,474	0
Margins (%)	26.2	21.6	24.5	25.4	21.6	20.3	20.4	22.1	24.4	21.1	19.5	
Depreciation	1,307	1,393	1,507	1,546	1,566	1,612	1,700	1,770	5,753	6,648	1,640	
Interest	325	445	620	659	656	793	770	740	2,048	2,959	650	
Other Income	99	327	100	223	118	291	110	309	749	828	360	
PBT before EO expense	8,665	6,542	6,460	7,614	5,095	4,339	5,018	6,794	29,280	21,246	4,544	
Extra-Ord expense & DO	249	361	150	280	237	191	0	0	1,040	428	0	
PBT	8,416	6,181	6,309	7,334	4,858	4,148	5,018	6,794	28,240	20,817	4,544	
Tax	2,336	1,371	1,200	1,709	1,265	1,140	1,228	1,663	6,617	5,297	1,112	
Rate (%)	27.0	21.0	18.6	22.5	24.8	26.3	24.5	24.5	22.6	24.9	24.5	
Reported PAT	6,080	4,810	5,109	5,625	3,593	3,008	3,789	5,131	21,623	15,521	3,431	
Adj PAT	6,329	5,171	5,259	5,905	3,830	3,199	3,789	5,131	22,663	15,949	3,431	-7
YoY Change (%)	63.1	42.9	11.4	-0.6	-39.5	-38.1	-28.0	-13.1	24.8	-29.6	-33.6	
Margins (%)	16.2	13.9	15.2	15.6	11.5	10.1	10.5	12.6	15.2	11.2	10.3	

Key Performance Indicators

Y/E March	FY23				FY24E				FY23	FY24E	FY24E
	1Q	2Q	3Q	4Q	1Q	2Q	3QE	4QE			
Consolidated											
Segment Revenue (INRm)											
Technical Textile	5,710	4,662	4,259	4,307	4,647	5,062	5,111	5,255	18,939	17,875	4,732
Chemicals	17,224	18,302	17,566	21,017	16,605	14,263	16,688	20,596	74,109	73,490	16,288
Packaging Film	14,960	13,310	12,027	11,531	10,948	11,215	13,229	13,837	51,828	47,816	11,047
Others	1,056	1,004	923	943	1,187	1,269	1,053	1,040	3,926	4,057	1,154
Segment Revenue Growth (%)											
Technical Textile	15.8	-16.4	-20.8	-13.3	-18.6	8.6	20.0	22.0	-9.2	6.0	5.3
Chemicals	54.7	62.5	23.0	33.7	-3.6	-22.1	-5.0	-2.0	41.4	-8.0	-18.1
Packaging Film	43.7	24.2	-5.7	-17.1	-26.8	-15.7	10.0	20.0	8.4	-5.0	-40.1
Other	96.9	16.3	-13.7	1.0	12.4	26.4	14.0	10.3	15.4	15.9	82.5
Segment Results (INRm)											
Technical Textile	1,162	629	342	484	607	750	818	920	2,617	3,093	662
Chemicals	5,202	5,173	5,639	7,393	4,601	3,478	4,172	5,355	23,407	17,605	4,235
Packaging Film	2,952	1,014	1,186	410	513	773	1,058	1,522	5,562	3,866	608
Others	68	76	91	113	232	331	189	187	348	939	139
Segment EBIT Margins (%)											
Technical Textile	20.4	13.5	8.0	11.2	13.1	14.8	16.0	17.5	13.8	15.4	14.0
Chemicals	30.2	28.3	32.1	35.2	27.7	24.4	25.0	26.0	31.6	25.8	26.0
Packaging Film	19.7	7.6	9.9	3.6	4.7	6.9	8.0	11.0	10.7	7.9	5.5
Others	6.4	7.6	9.9	12.0	19.5	26.1	18.0	18.0	8.9	20.6	12.0
Cost Break-up											
RM Cost (% of sales)	47.7	52.4	48.8	50.0	50.9	51.0	52.3	52.2	49.7	51.6	48.8
Staff Cost (% of sales)	5.0	5.2	6.1	5.7	6.5	7.1	6.4	5.7	5.5	6.4	6.1
Power and Fuel Cost (% of sales)	10.5	10.0	9.9	9.1	10.6	10.8	10.3	9.7	9.9	10.3	9.9
Other Cost (% of sales)	10.6	10.7	10.7	9.8	10.4	10.7	10.6	10.3	10.5	10.5	10.7
Gross Margins (%)	52.3	47.6	51.2	50.0	49.1	49.0	47.7	47.8	50.3	48.4	51.2
EBITDA Margins (%)	26.2	21.6	24.5	25.4	21.6	20.3	20.4	22.1	24.4	21.1	24.5
EBIT Margins (%)	22.8	17.9	20.1	21.3	16.9	15.2	15.7	17.7	20.6	16.5	20.1


Key Exhibits

Exhibit 1: Consolidated revenue trend




Source: Company, MOFSL

Exhibit 2: Consolidated EBITDA trend




Source: Company, MOFSL

Exhibit 3: Consolidated adjusted PAT trend




Source: Company, MOFSL

Exhibit 4: Revenue mix trend




Source: Company, MOFSL

Exhibit 5: EBIT mix trend




Source: Company, MOFSL

Exhibit 6: Revenue trend in Chemicals business




Source: Company, MOFSL

Exhibit 7: EBIT trend in Chemicals business




Source: Company, MOFSL

Exhibit 8: Revenue trend in Packaging Film business




Source: Company, MOFSL

Exhibit 9: EBIT trend in Packaging Film business




Source: Company, MOFSL

Exhibit 10: Revenue trend in Technical Textiles business



Source: Company, MOFSL

Exhibit 11: EBIT trend in Technical Textiles business



Source: Company, MOFSL



Key highlights from the management commentary

Chemicals business:

- **The Specialty Chemicals segment** performance was adversely impacted during the quarter due to inventory destocking (led by easing supply chain challenges post COVID) and working capital pressures at customer's end (cost of holding inventory has gone up due to increasing interest rate).
- The inventory rationalization currently seems transitory. The company is witnessing rescheduling of order and not cancellation.
- The company expects 3QFY24 to be better than 2QFY24 and 4QFY24 to be better than 3QFY24.
- Within agrochemicals, the management expects ongoing pressure on volumes to sustain in 2HFY24.
- However, the company is confident of at least single-digit growth in the specialty chemical business in full year FY24.
- SRF has launched six new products in 1HFY24 (four in Agro and two in Pharma). Further, it has a robust pipeline in place for new and complex products.
- The company is setting up a new facility to produce an agrochemical intermediate at Dahej at an estimated cost of INR2.35b.
- Further, the company is expected to commission projects worth ~INR11b in 2HFY24, which are likely to contribute to healthy growth in the near future.
- **Fluorochemicals segment** witnessed subdued performance as the Chinese dumping led to low demand and weak prices for the key refrigerants.
- Further, sluggish growth in pharmaceuticals and agrochemical industries adversely impacted demand for some industrial chemicals.
- However, SRF's market share in HFCs was higher despite the weak domestic market.
- Management expects stronger traction in demand in 2HFY24.
- The company has commissioned its PTFE facility, while the PX-1 and PX-2 facilities are expected to be capitalized in 2HFY24.
- SRF's R-32 facility is likely to be commissioned by mid Dec'23.
- Management aims to achieve flattish growth in Fluorochemicals for full-year FY24. However, the same is a difficult task and the company can witness revenue de-growth on YoY basis.
- Going ahead, key raw material prices are anticipated to remain stable.
- Domestic passenger vehicle market is witnessing healthy growth; this will be positive for the business going ahead.

Packaging Film business

- The business continued facing supply overhang and margin pressures with the commissioning of several new lines
- The company expects the demand-supply mismatch to continue in the near term, especially in BOPET films.
- Accordingly, the company is focusing on improving operational efficiencies, optimizing costs, and increasing contractual sales.
- The company has commissioned its Aluminum foil project and the commercial production of the same is expected to start soon.

- **Capacitor grade BOPP film project:** The company is setting up manufacturing facility for producing BOPP Film for Capacitor at an estimated cost of INR2.75b.
- The facility will have a manufacturing capacity of ~4,500 MTPA and is expected to be complete within 31 months.
- The company expects the IRR of the project to be in the range of ~16-18% with a payback period of ~5-5.5 years.
- The margins for these films will be higher than normal BOPP films.
- Currently, the demand for capacitor is ~40,000-50,000 tons per annum, while the capacity to produce it is just ~7,000 tons. Accordingly, majority of the requirements are imported. With the growing domestic EMS space in India, the situation is likely to change.
- Further, demand for the capacitor is growing by ~10% p.a. with major demand coming from consumer electronics and EV chargers.

Technical Textile business:

- The business recorded stable performance as underlying industries witnessed healthy demand trends.
- Belting fabric and Polyester Industrial Yarn witnessed better performance, led by enhanced focus on high-end value-added products.
- Expansion project in the Belting Fabrics and Polyester Industrial Yarn segment is progressing as per schedule.
- Going ahead, management expects improved demand in Belting Fabrics and Polyester Industrial Yarn segments on the back of the government's focus on infrastructure development.

Other businesses:

- SRF's coated fabric business achieved record quarterly sales and EBITDA as demand in storage liners and tarps witnessed healthy growth.
- For laminated fabric business, oversupply situation is likely to continue with new capacity addition coming in 2HFY24.

Capex:

- The company has incurred a capex of ~INR13b in 1HFY24 and plans to incur ~INR29-30b for full year FY24 (with ~80-85% of the capex to be incurred for chemical business).
- Similarly, it plans to incur a capex of ~INR28-30b in FY25 (with ~80% of the capex to be incurred for chemical business).

Valuation and view

- The Chemicals and Packaging business margins are expected to remain under pressure in FY24, led by weak demand scenario and lower realization. However, we expect the packaging performance to improve from FY25.
- We maintain our FY24/FY25 EBITDA estimates and value the stock at SoTP-based TP of INR2,000. We reiterate our NEUTRAL rating on the stock.

Exhibit 12: Valuation methodology

EV/EBITDA	FY25E EBITDA (INR m)	Multiple (x)	EV (INR m)
Technical Textiles	4,481	8	35,849
Chemicals	28,871	18	5,27,179
Packaging Films	9,836	8	78,691
Others	1,178	5	5,892
Total EV			6,47,610
Less: Debt			53,541
Less: Minority Interest			-
Add: Cash & Cash Equivalents			908
Target Mcap (INR m)			5,94,977
Outstanding share (m)			297.4
Target Price (INR)			2,000

Source: MOFSL

Exhibit 13: Revisions to our estimates

Earnings Change (INR m)	Old		New		Change (%)	
	FY24E	FY25E	FY24E	FY25E	FY24E	FY25E
Revenue	1,45,592	1,79,028	1,41,967	1,74,232	-2	-3
EBITDA	31,079	43,064	30,026	41,734	-3	-3
Adj. PAT	17,150	25,559	15,949	23,962	-7	-6

Source: MOFSL

Financials and valuations

Consolidated - Income Statement									(INRm)
Y/E March	FY17	FY18	FY19	FY20	FY21	FY22	FY23	FY24E	FY25E
Income from Operations	51,366	56,849	70,996	72,094	84,000	1,24,337	1,48,703	1,41,967	1,74,232
Less: Excise Duty	3,148	958	0	0	0	0	0	0	0
Total Income from Operations	48,218	55,890	70,996	72,094	84,000	1,24,337	1,48,703	1,41,967	1,74,232
Change (%)	5.0	15.9	27.0	1.5	16.5	48.0	19.6	-4.5	22.7
Cost of Materials Consumed	24,188	30,320	39,671	36,870	40,189	60,669	73,935	73,305	88,933
% of Sales	50.2	54.2	55.9	51.1	47.8	48.8	49.7	51.6	51.0
Personnel Expenses	4,338	4,740	4,608	5,419	6,214	7,800	8,138	9,096	9,234
% of Sales	9.0	8.5	6.5	7.5	7.4	6.3	5.5	6.4	5.3
Other Expenses	9,998	11,768	13,508	15,221	16,264	24,835	30,297	29,540	34,331
% of Sales	20.7	21.1	19.0	21.1	19.4	20.0	20.4	20.8	19.7
Total Expenditure	38,524	46,828	57,787	57,510	62,667	93,305	1,12,371	1,11,941	1,32,499
% of Sales	79.9	83.8	81.4	79.8	74.6	75.0	75.6	78.9	76.0
EBITDA	9,694	9,062	13,209	14,584	21,333	31,032	36,332	30,026	41,734
Margin (%)	20.1	16.2	18.6	20.2	25.4	25.0	24.4	21.1	24.0
Depreciation	2,834	3,158	3,582	3,886	4,531	5,172	5,753	6,648	8,028
EBIT	6,859	5,904	9,627	10,698	16,803	25,860	30,579	23,377	33,706
Int. and Finance Charges	1,018	1,239	1,984	2,007	1,340	1,159	2,048	2,959	2,960
Other Income	730	688	280	491	545	428	749	828	993
PBT bef. EO Exp.	6,572	5,353	7,923	9,182	16,008	25,128	29,280	21,246	31,739
EO Items	0	463	262	997	116	727	-1,040	-428	0
PBT after EO Exp.	6,572	5,817	8,185	10,179	16,123	25,856	28,240	20,817	31,739
Current Tax	1,422	1,200	1,769	265	4,154	7,139	6,617	5,297	7,777
Deferred Tax	0	0	0	-277	-10	-173	0	0	0
Tax Rate (%)	21.6	20.6	21.6	-0.1	25.7	26.9	23.4	25.4	24.5
Less: Minority Interest	0	0	0	0	0	0	0	0	0
Reported PAT	5,150	4,617	6,416	10,191	11,979	18,889	21,623	15,521	23,962
Adjusted PAT	5,150	4,154	6,155	9,194	11,864	18,162	22,663	15,949	23,962
Change (%)	17.0	-19.3	48.2	49.4	29.0	53.1	24.8	-29.6	50.2
Margin (%)	10.7	7.4	8.7	12.8	14.1	14.6	15.2	11.2	13.8

Consolidated - Balance Sheet									(INRm)
Y/E March	FY17	FY18	FY19	FY20	FY21	FY22	FY23	FY24E	FY25E
Equity Share Capital	574	575	575	585	603	2,974	2,974	2,974	2,974
Preference Capital	0	0	0	0	0	0	0	0	0
Total Reserves	31,252	35,071	40,718	48,748	67,962	82,679	1,00,296	1,12,247	1,31,748
Net Worth	31,826	35,646	41,293	49,333	68,564	85,654	1,03,271	1,15,222	1,34,722
Minority Interest	0	0	0	0	0	0	0	0	0
Deferred Liabilities	2,866	2,914	3,420	1,755	3,862	6,775	8,092	8,092	8,092
Total Loans	23,962	31,418	37,302	40,468	33,950	35,394	43,541	48,541	53,541
Capital Employed	58,655	69,978	82,014	91,556	1,06,376	1,27,822	1,54,903	1,71,855	1,96,355
Gross Block	77,169	87,502	68,322	76,934	96,167	1,06,943	1,28,622	1,60,622	1,88,622
Less: Accum. Deprn.	33,169	36,327	12,269	15,540	20,071	25,243	30,997	37,645	45,672
Net Fixed Assets	44,000	51,175	56,053	61,394	76,096	81,699	97,626	1,22,978	1,42,950
Goodwill on Consolidation	49	41	41	6	6	0	0	0	0
Capital WIP	2,586	5,588	7,536	13,933	7,723	16,716	24,055	21,055	21,055
Current Investments	1,708	1,217	1,005	1,985	4,125	3,167	4,901	4,901	4,901
Total Investments	1,959	1,218	1,006	2,027	4,167	3,209	4,942	4,942	4,942
Curr. Assets, Loans&Adv.	21,090	25,608	34,243	31,265	41,121	56,025	60,735	56,078	66,377
Inventory	8,381	9,582	12,247	12,012	14,658	21,385	22,743	21,690	26,314
Account Receivables	6,569	6,807	10,288	8,911	12,746	17,925	17,856	17,503	21,481
Cash and Bank Balance	961	967	1,989	1,255	2,820	4,594	6,165	1,516	908
Loans and Advances	5,178	8,252	9,719	9,088	10,898	12,123	13,972	15,369	17,674
Curr. Liability & Prov.	11,055	13,653	16,865	17,211	22,918	29,944	32,642	33,385	39,156
Account Payables	8,089	10,442	13,824	11,117	15,852	20,964	22,313	22,092	26,802
Other Current Liabilities	2,606	2,831	2,600	5,653	6,544	8,391	9,642	10,606	11,667
Provisions	359	380	441	442	522	590	687	687	687
Net Current Assets	10,035	11,955	17,378	14,054	18,203	26,081	28,093	22,693	27,221
Deferred Tax assets	26	0	0	143	181	116	187	187	187
Appl. of Funds	58,655	69,978	82,014	91,556	1,06,376	1,27,822	1,54,903	1,71,855	1,96,355

Financials and valuations

Ratios

Y/E March	FY17	FY18	FY19	FY20	FY21	FY22	FY23	FY24E	FY25E
Basic (INR)									
EPS	17.3	14.0	20.7	30.9	39.9	61.1	76.2	53.6	80.6
Cash EPS	26.8	24.6	32.7	44.0	55.1	78.5	95.5	76.0	107.6
BV/Share	107.0	119.8	138.8	165.9	230.5	288.0	347.2	387.4	452.9
DPS	2.3	3.1	3.9	2.8	4.9	16.8	7.2	12.0	15.0
Payout (%)	15.7	23.1	20.8	9.6	12.1	26.4	9.9	23.0	18.6
Valuation (x)									
P/E	126.1	156.3	105.5	70.6	54.7	35.7	28.6	40.7	27.1
Cash P/E	81.3	88.8	66.7	49.6	39.6	27.8	22.8	28.7	20.3
P/BV	20.4	18.2	15.7	13.2	9.5	7.6	6.3	5.6	4.8
EV/Sales	13.9	12.1	9.6	9.5	8.0	5.4	4.6	4.9	4.0
EV/EBITDA	69.2	74.9	51.7	47.1	31.7	21.8	18.8	23.0	16.7
Dividend Yield (%)	0.1	0.1	0.2	0.1	0.2	0.8	0.3	0.5	0.7
FCF per share	0.2	-20.3	-5.3	-2.3	19.1	9.7	0.0	-10.5	6.1
Return Ratios (%)									
EBITDA Margins (%)	20.1	16.2	18.6	20.2	25.4	25.0	24.4	21.1	24.0
Net Profit Margins (%)	10.7	7.4	8.7	12.8	14.1	14.6	15.2	11.2	13.8
RoE	17.3	12.3	16.0	20.3	20.1	23.6	24.0	14.6	19.2
RoCE	11.0	8.5	10.7	13.3	13.4	17.2	17.9	11.6	14.9
RoIC	17.8	13.8	18.0	15.3	26.3	34.2	34.7	23.0	27.5
Working Capital Ratios									
Accum. Dep/Gross Block (x)	0	0	0	0	0	0	0	0	0
Fixed Asset Turnover (x)	0.6	0.6	1.0	0.9	0.9	1.2	1.2	0.9	0.9
Asset Turnover (x)	0.8	0.8	0.9	0.8	0.8	1.0	1.0	0.8	0.9
Inventory (Days)	126	115	113	119	133	129	112	108	108
Debtor (Days)	50	44	53	45	55	53	44	45	45
Creditor (Days)	122	126	127	110	144	126	110	110	110
Working Cap. Turnover (Days)	69	72	79	65	67	63	54	54	55
Leverage Ratio (x)									
Current Ratio	1.9	1.9	2.0	1.8	1.8	1.9	1.9	1.7	1.7
Interest Cover Ratio	7	5	5	5	13	22	15	8	11
Debt/Equity	0.8	0.9	0.9	0.8	0.5	0.4	0.4	0.4	0.4

Consolidated - Cash Flow Statement

Y/E March	FY17	FY18	FY19	FY20	FY21	FY22	FY23	FY24E	FY25E
OP/(Loss) before Tax	6,572	5,817	8,269	10,706	16,099	25,856	28,240	20,817	31,739
Depreciation	2,834	3,158	3,669	3,929	4,531	5,172	5,753	6,648	8,028
Interest & Finance Charges	1,018	1,239	2,016	2,016	1,340	1,159	2,048	2,959	2,960
Direct Taxes Paid	-1,159	-1,176	-1,502	-1,427	-2,553	-4,016	-6,617	-5,297	-7,777
(Inc)/Dec in WC	-2,556	-1,909	-3,165	-239	-1,236	-6,645	-408	752	-5,137
CF from Operations	6,709	7,129	9,286	14,984	18,181	21,527	29,017	25,881	29,813
Others	-255	-349	-330	-1,940	-464	-469	0	0	0
CF from Operating incl EO	6,454	6,780	8,956	13,044	17,717	21,057	29,017	25,881	29,813
(inc)/dec in FA	-6,409	-12,829	-10,526	-13,730	-12,047	-18,171	-29,019	-29,000	-28,000
Free Cash Flow	45	-6,049	-1,570	-685	5,670	2,886	-2	-3,119	1,813
(Pur)/Sale of Investments	25	840	332	-886	-1,886	1,028	-1,733	0	0
Others	251	35	53	2,813	-1,064	1,265	1,138	0	0
CF from Investments	-6,133	-11,953	-10,142	-11,803	-14,997	-15,877	-29,614	-29,000	-28,000
Issue of Shares	0	0	1	0	7,500	2	0	0	0
Inc/(Dec) in Debt	-4,552	4,095	2,677	3,205	-6,856	622	8,147	5,000	5,000
Interest Paid	-1,109	-1,299	-2,241	-2,040	-1,574	-1,173	-2,048	-2,959	-2,960
Dividend Paid	-829	-829	-836	-803	-1,408	-2,117	-2,142	-3,569	-4,462
Others	3,731	3,213	2,606	-2,337	1,182	-741	-1,789	0	0
CF from Fin. Activity	-2,760	5,179	2,207	-1,975	-1,155	-3,406	2,168	-1,528	-2,422
Inc/Dec of Cash	-2,438	6	1,021	-734	1,565	1,774	1,571	-4,648	-609
Opening Balance	3,399	961	967	1,989	1,255	2,820	4,594	6,164	1,516
Closing Balance	961	967	1,989	1,255	2,820	4,594	6,164	1,516	908

Investment in securities market are subject to market risks. Read all the related documents carefully before investing

NOTES

Explanation of Investment Rating	
Investment Rating	Expected return (over 12-month)
BUY	>=15%
SELL	< - 10%
NEUTRAL	< - 10 % to 15%
UNDER REVIEW	Rating may undergo a change
NOT RATED	We have forward looking estimates for the stock but we refrain from assigning recommendation

*In case the recommendation given by the Research Analyst is inconsistent with the investment rating legend for a continuous period of 30 days, the Research Analyst shall be within following 30 days take appropriate measures to make the recommendation consistent with the investment rating legend.

Disclosures

The following Disclosures are being made in compliance with the SEBI Research Analyst Regulations 2014 (herein after referred to as the Regulations).

Motilal Oswal Financial Services Ltd. (MOFSL) is a SEBI Registered Research Analyst having registration no. INH000000412. MOFSL, the Research Entity (RE) as defined in the Regulations, is engaged in the business of providing Stock broking services, Depository participant services & distribution of various financial products. MOFSL is a listed public company, the details in respect of which are available on www.motilaloswal.com. MOFSL (erstwhile Motilal Oswal Securities Limited - MOSL) is registered with the Securities & Exchange Board of India (SEBI) and is a registered Trading Member with National Stock Exchange of India Ltd. (NSE) and Bombay Stock Exchange Limited (BSE), Multi Commodity Exchange of India Limited (MCX) and National Commodity & Derivatives Exchange Limited (NCDEX) for its stock broking activities & is Depository participant with Central Depository Services Limited (CDSL) National Securities Depository Limited (NSDL), NERL, COMRIS and CCRL and is member of Association of Mutual Funds of India (AMFI) for distribution of financial products and Insurance Regulatory & Development Authority of India (IRDA) as Corporate Agent for insurance products. Details of associate entities of Motilal Oswal Financial Services Limited are available on the website at <http://onlinereports.motilaloswal.com/Dormant/documents/List%20of%20Associate%20companies.pdf>

MOFSL and its associate company(ies), their directors and Research Analyst and their relatives may; (a) from time to time, have a long or short position in, act as principal in, and buy or sell the securities or derivatives thereof of companies mentioned herein. (b) be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the company(ies) discussed herein or act as an advisor or lender/borrower to such company(ies) or may have any other potential conflict of interests with respect to any recommendation and other related information and opinions.; however the same shall have no bearing whatsoever on the specific recommendations made by the analyst(s), as the recommendations made by the analyst(s) are completely independent of the views of the associates of MOFSL even though there might exist an inherent conflict of interest in some of the stocks mentioned in the research report.

MOFSL and / or its affiliates do and seek to do business including investment banking with companies covered in its research reports. As a result, the recipients of this report should be aware that MOFSL may have a potential conflict of interest that may affect the objectivity of this report. Compensation of Research Analysts is not based on any specific merchant banking, investment banking or brokerage service transactions. Details of pending Enquiry Proceedings of Motilal Oswal Financial Services Limited are available on the website at <https://galaxy.motilaloswal.com/ResearchAnalyst/PublishViewLitigation.aspx>

A graph of daily closing prices of securities is available at www.nseindia.com, www.bseindia.com. Research Analyst views on Subject Company may vary based on Fundamental research and Technical Research. Proprietary trading desk of MOFSL or its associates maintains arm's length distance with Research Team as all the activities are segregated from MOFSL research activity and therefore it can have an independent view with regards to Subject Company for which Research Team have expressed their views.

Regional Disclosures (outside India)

This report is not directed or intended for distribution to or use by any person or entity resident in a state, country or any jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject MOFSL & its group companies to registration or licensing requirements within such jurisdictions.

For Hong Kong:

This report is distributed in Hong Kong by Motilal Oswal capital Markets (Hong Kong) Private Limited, a licensed corporation (CE AYY-301) licensed and regulated by the Hong Kong Securities and Futures Commission (SFC) pursuant to the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) "SFO". As per SEBI (Research Analyst Regulations) 2014 Motilal Oswal Securities (SEBI Reg. No. INH000000412) has an agreement with Motilal Oswal capital Markets (Hong Kong) Private Limited for distribution of research report in Hong Kong. This report is intended for distribution only to "Professional Investors" as defined in Part I of Schedule 1 to SFO. Any investment or investment activity to which this document relates is only available to professional investor and will be engaged only with professional investors." Nothing here is an offer or solicitation of these securities, products and services in any jurisdiction where their offer or sale is not qualified or exempt from registration. The Indian Analyst(s) who compile this report is/are not located in Hong Kong & are not conducting Research Analysis in Hong Kong.

For U.S.

Motilal Oswal Financial Services Limited (MOFSL) is not a registered broker - dealer under the U.S. Securities Exchange Act of 1934, as amended (the "1934 act") and under applicable state laws in the United States. In addition MOFSL is not a registered investment adviser under the U.S. Investment Advisers Act of 1940, as amended (the "Advisers Act" and together with the 1934 Act, the "Acts"), and under applicable state laws in the United States. Accordingly, in the absence of specific exemption under the Acts, any brokerage and investment services provided by MOFSL, including the products and services described herein are not available to or intended for U.S. persons. This report is intended for distribution only to "Major Institutional Investors" as defined by Rule 15a-6(b)(4) of the Exchange Act and interpretations thereof by SEC (henceforth referred to as "major institutional investors"). This document must not be acted on or relied on by persons who are not major institutional investors. Any investment or investment activity to which this document relates is only available to major institutional investors and will be engaged in only with major institutional investors. In reliance on the exemption from registration provided by Rule 15a-6 of the U.S. Securities Exchange Act of 1934, as amended (the "Exchange Act") and interpretations thereof by the U.S. Securities and Exchange Commission ("SEC") in order to conduct business with Institutional Investors based in the U.S., MOFSL has entered into a chaperoning agreement with a U.S. registered broker-dealer, Motilal Oswal Securities International Private Limited. ("MOSIPL"). Any business interaction pursuant to this report will have to be executed within the provisions of this chaperoning agreement.

The Research Analysts contributing to the report may not be registered /qualified as research analyst with FINRA. Such research analyst may not be associated persons of the U.S. registered broker-dealer, MOSIPL, and therefore, may not be subject to NASD rule 2711 and NYSE Rule 472 restrictions on communication with a subject company, public appearances and trading securities held by a research analyst account.

For Singapore

In Singapore, this report is being distributed by Motilal Oswal Capital Markets Singapore Pte Ltd ("MOCMSPL") (Co. Reg. NO. 201129401Z) which is a holder of a capital markets services license and an exempt financial adviser in Singapore. As per the approved agreement under Paragraph 9 of Third Schedule of Securities and Futures Act (CAP 289) and Paragraph 11 of First Schedule of Financial Advisors Act (CAP 110) provided to MOCMSPL by Monetary Authority of Singapore. Persons in Singapore should contact MOCMSPL in respect of any matter arising from, or in connection with this report/publication/communication. This report is distributed solely to persons who qualify as "Institutional Investors", of which some of whom may consist of "accredited" institutional investors as defined in section 4A(1) of the Securities and Futures Act, Chapter 289 of Singapore ("the SFA"). Accordingly, if a Singapore person is not or ceases to be such an institutional investor, such Singapore Person must immediately discontinue any use of this Report and inform MOCMSPL.

Specific Disclosures

- 1 MOFSL, Research Analyst and/or his relatives does not have financial interest in the subject company, as they do not have equity holdings in the subject company.
- 2 MOFSL, Research Analyst and/or his relatives do not have actual/beneficial ownership of 1% or more securities in the subject company
- 3 MOFSL, Research Analyst and/or his relatives have not received compensation/other benefits from the subject company in the past 12 months
- 4 MOFSL, Research Analyst and/or his relatives do not have material conflict of interest in the subject company at the time of publication of research report
- 5 Research Analyst has not served as director/officer/employee in the subject company
- 6 MOFSL has not acted as a manager or co-manager of public offering of securities of the subject company in past 12 months
- 7 MOFSL has not received compensation for investment banking/ merchant banking/brokerage services from the subject company in the past 12 months
- 8 MOFSL has not received compensation for other than investment banking/merchant banking/brokerage services from the subject company in the past 12 months
- 9 MOFSL has not received any compensation or other benefits from third party in connection with the research report
- 10 MOFSL has not engaged in market making activity for the subject company

The associates of MOFSL may have:

- financial interest in the subject company
- actual/beneficial ownership of 1% or more securities in the subject company at the end of the month immediately preceding the date of publication of the Research Report or date of the public appearance.
- received compensation/other benefits from the subject company in the past 12 months
- any other potential conflict of interests with respect to any recommendation and other related information and opinions.; however the same shall have no bearing whatsoever on the specific recommendations made by the analyst(s), as the recommendations made by the analyst(s) are completely independent of the views of the associates of MOFSL even though there might exist an inherent conflict of interest in some of the stocks mentioned in the research report.
- acted as a manager or co-manager of public offering of securities of the subject company in past 12 months
- be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the company(ies) discussed herein or act as an advisor or lender/borrower to such company(ies)
- received compensation from the subject company in the past 12 months for investment banking / merchant banking / brokerage services or from other than said services.
- Served subject company as its clients during twelve months preceding the date of distribution of the research report.

The associates of MOFSL has not received any compensation or other benefits from third party in connection with the research report

Above disclosures include beneficial holdings lying in demat account of MOFSL which are opened for proprietary investments only. While calculating beneficial holdings, It does not consider demat accounts which are opened in name of MOFSL for other purposes (i.e holding client securities, collaterals, error trades etc.). MOFSL also earns DP income from clients which are not considered in above disclosures.

Analyst Certification

The views expressed in this research report accurately reflect the personal views of the analyst(s) about the subject securities or issues, and no part of the compensation of the research analyst(s) was, is, or will be directly or indirectly related to the specific recommendations and views expressed by research analyst(s) in this report.

Terms & Conditions:

This report has been prepared by MOFSL and is meant for sole use by the recipient and not for circulation. The report and information contained herein is strictly confidential and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of MOFSL. The report is based on the facts, figures and information that are considered true, correct, reliable and accurate. The intent of this report is not recommendatory in nature. The information is obtained from publicly available media or other sources believed to be reliable. Such information has not been independently verified and no guaranty, representation of warranty, express or implied, is made as to its accuracy, completeness or correctness. All such information and opinions are subject to change without notice. The report is prepared solely for informational purpose and does not constitute an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments for the clients. Though disseminated to all the customers simultaneously, not all customers may receive this report at the same time. MOFSL will not treat recipients as customers by virtue of their receiving this report.

Disclaimer:

The report and information contained herein is strictly confidential and meant solely for the selected recipient and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent. This report and information herein is solely for informational purpose and may not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Nothing in this report constitutes investment, legal, accounting and tax advice or a representation that any investment or strategy is suitable or appropriate to your specific circumstances. The securities discussed and opinions expressed in this report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient. This may not be taken in substitution for the exercise of independent judgment by any recipient. Each recipient of this document should make such investigations as it deems necessary to arrive at an independent evaluation of an investment in the securities of companies referred to in this document (including the merits and risks involved), and should consult its own advisors to determine the merits and risks of such an investment. The investment discussed or views expressed may not be suitable for all investors. Certain transactions -including those involving futures, options, another derivative products as well as non-investment grade securities - involve substantial risk and are not suitable for all investors. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information and opinions contained in this document. The Disclosures of Interest Statement incorporated in this document is provided solely to enhance the transparency and should not be treated as endorsement of the views expressed in the report. This information is subject to change without any prior notice. The Company reserves the right to make modifications and alternations to this statement as may be required from time to time without any prior approval. MOFSL, its associates, their directors and the employees may from time to time, effect or have effected an own account transaction in, or deal as principal or agent in or for the securities mentioned in this document. They may perform or seek to perform investment banking or other services for, or solicit investment banking or other business from, any company referred to in this report. Each of these entities functions as a separate, distinct and independent of each other. The recipient should take this into account before interpreting the document. This report has been prepared on the basis of information that is already available in publicly accessible media or developed through analysis of MOFSL. The views expressed are those of the analyst, and the Company may or may not subscribe to all the views expressed therein. This document is being supplied to you solely for your information and may not be reproduced, redistributed or passed on, directly or indirectly, to any other person or published, copied, in whole or in part, for any purpose. This report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject MOFSL to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors. Persons in whose possession this document may come are required to inform themselves of and to observe such restriction. Neither the Firm, not its directors, employees, agents or representatives shall be liable for any damages whether direct or indirect, incidental, special or consequential including lost revenue or lost profits that may arise from or in connection with the use of the information. The person accessing this information specifically agrees to exempt MOFSL or any of its affiliates or employees from, any and all responsibility/liability arising from such misuse and agrees not to hold MOFSL or any of its affiliates or employees responsible for any such misuse and further agrees to hold MOFSL or any of its affiliates or employees free and harmless from all losses, costs, damages, expenses that may be suffered by the person accessing this information due to any errors and delays.

This report is meant for the clients of Motilal Oswal only.

Investment in securities market are subject to market risks. Read all the related documents carefully before investing.

Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

Registered Office Address: Motilal Oswal Tower, Rahimtullah Sayani Road, Opposite Parel ST Depot, Prabhadevi, Mumbai-400025; Tel No.: 022 - 71934200 / 71934263;

www.motilaloswal.com. Correspondence Address: Palm Spring Centre, 2nd Floor, Palm Court Complex, New Link Road, Malad (West), Mumbai- 400 064. Tel No: 022 71881000.

Details of Compliance Officer: Neeraj Agarwal, Email Id: na@motilaloswal.com, Contact No.:022-40548085.

Grievance Redressal Cell:

Contact Person	Contact No.	Email ID
Ms. Hemangi Date	022 40548000 / 022 67490600	query@motilaloswal.com
Ms. Kumud Upadhyay	022 40548082	servicehead@motilaloswal.com
Mr. Ajay Menon	022 40548083	am@motilaloswal.com

Registration details of group entities.: Motilal Oswal Financial Services Ltd. (MOFSL): INZ000158836 (BSE/NSE/MCX/NCDEX); CDSL and NSDL: IN-DP-16-2015; Research Analyst: INH000000412 . AMFI: ARN .: 146822. IRDA Corporate Agent – CA0579. Motilal Oswal Financial Services Ltd. is a distributor of Mutual Funds, PMS, Fixed Deposit, Insurance, Bond, NCDs and IPO products.

Customer having any query/feedback/ clarification may write to query@motilaloswal.com. In case of grievances for any of the services rendered by Motilal Oswal Financial Services Limited (MOFSL) write to grievances@motilaloswal.com, for DP to dpgrievances@motilaloswal.com.